Skip to main content

Articles By Jack Cush, MD

risk2h.jpg

Risk vs. Benefit Lessons from the ORAL Surveillance Study

By Jack Cush, MD
27 January 2022

In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.

Read Article
phys.therapy.knee2_.jpg

Physical Therapy is More Cost-Effective than Intraarticular Steroids in Knee OA

By Jack Cush, MD
26 January 2022

A randomized trial compared the incremental cost-effectiveness of physical therapy and intra-articular glucocorticoid (IA GC) injection as initial treatment for knee osteoarthritis showed that physical therapy gained more quality-adjusted life-years compared with those receiving glucocorticoid in

Read Article
renal.stone_.LBP_.jpg

Allopurinol Safety in CKD Patients

By Jack Cush, MD
26 January 2022

A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.

Read Article
FDA.approved.jpg

FDA Approves Skyrizi for Active Psoriatic Arthritis

By Jack Cush, MD
24 January 2022

On Friday, the U.S. Food and Drug Administration (FDA) approved risankizumab-rzaa (Skyrizi) for the treatment of adults with active psoriatic arthritis (PsA), with similar dosing in plaque psoriasis - a single 150mg subcutaneous injection four times a year after two starter doses (at weeks 0 and

Read Article
RheumNow Podcast square

Believing is Doing (1.21.2022)

By Jack Cush, MD
20 January 2022

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. These reports are about better outcomes in Lupus; fewer Gout flares with T2T and the power of belief. 

Read Article
syringe,needle,vaccine

3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients

By Jack Cush, MD
20 January 2022

ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third

Read Article
shingles2.jpg

Herpes Zoster Vaccination in Immunocompromised Adults

By Jack Cush, MD
20 January 2022

The CDC's Advisory Committee on Immunization Practices (ACIP) recently recommended and approved two doses of the recombinant zoster vaccine (RZV, AKA Shingrix) for prevention of herpes zoster and complications in immunodeficient or immunosuppressed adults aged ≥19 years.

Read Article
hands.stiff2_.jpg

Referral Rules for At-Risk Inflammatory Arthritis

By Jack Cush, MD
19 January 2022

A prospective primary care study of patients at-risk for inflammatory arthritis (IA) showed that progression to IA was most likely in those with high anti-CCP antibody titers levels and involvement of the hands/feet/ IA.

Read Article
group,office,people,glue,work

Who is Your Glue?

By Jack Cush, MD
19 January 2022

I’ve often talked about the nurses in my clinic as being the glue, the clinic glue, my personal glue. Without them, the day and task would never go as well and just might crash and burn, if not for their steadying influence.

Read Article
xray%20spine%20films_0.jpg

BE MOBILE 1 Study - Bimekizumab in Non-Radiographic Axial Spondyloarthritis

By Jack Cush, MD
18 January 2022

Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Read Article
×